在医疗保险受益者中使用 gabapentin 的模式和特征
GYeon Oh1, Daniela C Moga2,3,4,5, Patricia R Freeman3,4
1Department of Epidemiology and Environmental Health, University of Kentucky, Lexington, KY, USA. gyeon.oh@uky.edu.
Drugs & aging
|October 17, 2025
概括
加巴丁的处方在老年人中增加,通常用于未经批准的用途,如慢性疼痛,经常与阿片类药物一起配方处方. 长期使用与更多的慢性疾病和较少的阿片类药物联合处方有关.
科学领域:
- 老年医学 老年医学
- 药理学 药理学是指药理学的学科.
- 医疗保健服务研究 医疗服务研究
背景情况:
- 在老年患者中, gabapentin (GBP) 的使用正在增加,但处方趋势和患者个人资料尚不清楚.
- 了解老年人中的GBP启动模式对于优化其使用和患者安全至关重要.
研究的目的:
- 在一大群老年人中调查 gabapentin 发起者的处方模式和特征.
- 确定与 gabapentin 使用相关的因素,并探索其在医疗保险人口中的适用性.
主要方法:
- 医疗保险服务费受益人的回顾性队列研究 (2012-2021年).
- 确定了加巴丁发起剂,其洗期为180天.
- 分析了人口统计,并发症,药物历史和医疗保健利用情况.
主要成果:
- 在2013年至2021年期间, gabapentin的处方从6.7%增加到10.2%.
- 慢性疼痛 (32.6%) 是最常见的启动原因,未经批准的指示 (,后神经疼痛<0.5%).
- 38.9%的人以前曾使用过阿片类药物; 13.2%的人在开始时同时服用 gabapentin 和阿片类药物. 长期使用 (>180天) 与更多的慢性疾病和较少的阿片类药物联合处方有关.
结论:
- 加巴丁经常被非标签处方用于治疗老年人的慢性疼痛,这些老年人患有多种并发症.
- 与阿片类药物的联合处方在开始时很常见,突出显示了潜在的安全问题.
- 需要进一步研究推动长期使用 gabapentin 的因素及其在这个人群中的适用性.
相关概念视频
Antiepileptic Drugs: Potassium Channel Activators
586
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
586
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
201
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
201
Pharmacodynamics in Geriatric Patients: Effects of Age
172
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
172
Drug Dosing: Geriatric Patients
199
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
199
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
176
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
176
Antiepileptic Drugs: GABAergic Pathway Potentiators
1.1K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.1K


